Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells

Francesca Chiarini, Camilla Evangelisti, Giovanna Lattanzi, James A McCubrey, Alberto M Martelli

Research output: Contribution to journalReview article

Abstract

The development of drug-resistance by neoplastic cells is recognized as a major cause of targeted therapy failure and disease progression. The mechanistic (previously mammalian) target of rapamycin (mTOR) is a highly conserved Ser/Thr kinase that acts as the catalytic subunit of two structurally and functionally distinct large multiprotein complexes, referred to as mTOR complex 1 (mTORC1) and mTORC2. Both mTORC1 and mTORC2 play key roles in a variety of healthy cell types/tissues by regulating physiological anabolic and catabolic processes in response to external cues. However, a body of evidence identified aberrant activation of mTOR signaling as a common event in many human tumors. Therefore, mTOR is an attractive target for therapeutic targeting in cancer and this fact has driven the development of numerous mTOR inhibitors, several of which have progressed to clinical trials. Nevertheless, mTOR inhibitors have met with a very limited success as anticancer therapeutics. Among other reasons, this failure was initially ascribed to the activation of several compensatory signaling pathways that dampen the efficacy of mTOR inhibitors. The discovery of these regulatory feedback mechanisms greatly contributed to a better understanding of cancer cell resistance to mTOR targeting agents. However, over the last few years, other mechanisms of resistance have emerged, including epigenetic alterations, compensatory metabolism rewiring and the occurrence of mTOR mutations. In this article, we provide the reader with an updated overview of the mechanisms that could explain resistance of cancer cells to the various classes of mTOR inhibitors.

Original languageEnglish
Pages (from-to)1322-1337
Number of pages16
JournalBiochimica et Biophysica Acta - Molecular Cell Research
Volume1866
Issue number8
Early online dateMar 27 2019
DOIs
Publication statusPublished - Sep 2019

Fingerprint

Sirolimus
Neoplasms
Inhibition (Psychology)
Multiprotein Complexes
Drug Resistance
Epigenomics
Cues
Disease Progression
Catalytic Domain
Phosphotransferases
Therapeutics
Clinical Trials
Mutation

Keywords

  • Cell signaling pathways
  • Drug-resistance
  • Epigenetics
  • Metabolism
  • Mutations
  • Target therapies

Cite this

Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. / Chiarini, Francesca; Evangelisti, Camilla; Lattanzi, Giovanna; McCubrey, James A; Martelli, Alberto M.

In: Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1866, No. 8, 09.2019, p. 1322-1337.

Research output: Contribution to journalReview article

Chiarini, Francesca ; Evangelisti, Camilla ; Lattanzi, Giovanna ; McCubrey, James A ; Martelli, Alberto M. / Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. In: Biochimica et Biophysica Acta - Molecular Cell Research. 2019 ; Vol. 1866, No. 8. pp. 1322-1337.
@article{98002c7544f94b7eb99463452b13b688,
title = "Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells",
abstract = "The development of drug-resistance by neoplastic cells is recognized as a major cause of targeted therapy failure and disease progression. The mechanistic (previously mammalian) target of rapamycin (mTOR) is a highly conserved Ser/Thr kinase that acts as the catalytic subunit of two structurally and functionally distinct large multiprotein complexes, referred to as mTOR complex 1 (mTORC1) and mTORC2. Both mTORC1 and mTORC2 play key roles in a variety of healthy cell types/tissues by regulating physiological anabolic and catabolic processes in response to external cues. However, a body of evidence identified aberrant activation of mTOR signaling as a common event in many human tumors. Therefore, mTOR is an attractive target for therapeutic targeting in cancer and this fact has driven the development of numerous mTOR inhibitors, several of which have progressed to clinical trials. Nevertheless, mTOR inhibitors have met with a very limited success as anticancer therapeutics. Among other reasons, this failure was initially ascribed to the activation of several compensatory signaling pathways that dampen the efficacy of mTOR inhibitors. The discovery of these regulatory feedback mechanisms greatly contributed to a better understanding of cancer cell resistance to mTOR targeting agents. However, over the last few years, other mechanisms of resistance have emerged, including epigenetic alterations, compensatory metabolism rewiring and the occurrence of mTOR mutations. In this article, we provide the reader with an updated overview of the mechanisms that could explain resistance of cancer cells to the various classes of mTOR inhibitors.",
keywords = "Cell signaling pathways, Drug-resistance, Epigenetics, Metabolism, Mutations, Target therapies",
author = "Francesca Chiarini and Camilla Evangelisti and Giovanna Lattanzi and McCubrey, {James A} and Martelli, {Alberto M}",
note = "Copyright {\circledC} 2019. Published by Elsevier B.V.",
year = "2019",
month = "9",
doi = "10.1016/j.bbamcr.2019.03.013",
language = "English",
volume = "1866",
pages = "1322--1337",
journal = "Biochimica et Biophysica Acta - Molecular Cell Research",
issn = "0167-4889",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells

AU - Chiarini, Francesca

AU - Evangelisti, Camilla

AU - Lattanzi, Giovanna

AU - McCubrey, James A

AU - Martelli, Alberto M

N1 - Copyright © 2019. Published by Elsevier B.V.

PY - 2019/9

Y1 - 2019/9

N2 - The development of drug-resistance by neoplastic cells is recognized as a major cause of targeted therapy failure and disease progression. The mechanistic (previously mammalian) target of rapamycin (mTOR) is a highly conserved Ser/Thr kinase that acts as the catalytic subunit of two structurally and functionally distinct large multiprotein complexes, referred to as mTOR complex 1 (mTORC1) and mTORC2. Both mTORC1 and mTORC2 play key roles in a variety of healthy cell types/tissues by regulating physiological anabolic and catabolic processes in response to external cues. However, a body of evidence identified aberrant activation of mTOR signaling as a common event in many human tumors. Therefore, mTOR is an attractive target for therapeutic targeting in cancer and this fact has driven the development of numerous mTOR inhibitors, several of which have progressed to clinical trials. Nevertheless, mTOR inhibitors have met with a very limited success as anticancer therapeutics. Among other reasons, this failure was initially ascribed to the activation of several compensatory signaling pathways that dampen the efficacy of mTOR inhibitors. The discovery of these regulatory feedback mechanisms greatly contributed to a better understanding of cancer cell resistance to mTOR targeting agents. However, over the last few years, other mechanisms of resistance have emerged, including epigenetic alterations, compensatory metabolism rewiring and the occurrence of mTOR mutations. In this article, we provide the reader with an updated overview of the mechanisms that could explain resistance of cancer cells to the various classes of mTOR inhibitors.

AB - The development of drug-resistance by neoplastic cells is recognized as a major cause of targeted therapy failure and disease progression. The mechanistic (previously mammalian) target of rapamycin (mTOR) is a highly conserved Ser/Thr kinase that acts as the catalytic subunit of two structurally and functionally distinct large multiprotein complexes, referred to as mTOR complex 1 (mTORC1) and mTORC2. Both mTORC1 and mTORC2 play key roles in a variety of healthy cell types/tissues by regulating physiological anabolic and catabolic processes in response to external cues. However, a body of evidence identified aberrant activation of mTOR signaling as a common event in many human tumors. Therefore, mTOR is an attractive target for therapeutic targeting in cancer and this fact has driven the development of numerous mTOR inhibitors, several of which have progressed to clinical trials. Nevertheless, mTOR inhibitors have met with a very limited success as anticancer therapeutics. Among other reasons, this failure was initially ascribed to the activation of several compensatory signaling pathways that dampen the efficacy of mTOR inhibitors. The discovery of these regulatory feedback mechanisms greatly contributed to a better understanding of cancer cell resistance to mTOR targeting agents. However, over the last few years, other mechanisms of resistance have emerged, including epigenetic alterations, compensatory metabolism rewiring and the occurrence of mTOR mutations. In this article, we provide the reader with an updated overview of the mechanisms that could explain resistance of cancer cells to the various classes of mTOR inhibitors.

KW - Cell signaling pathways

KW - Drug-resistance

KW - Epigenetics

KW - Metabolism

KW - Mutations

KW - Target therapies

U2 - 10.1016/j.bbamcr.2019.03.013

DO - 10.1016/j.bbamcr.2019.03.013

M3 - Review article

C2 - 30928610

VL - 1866

SP - 1322

EP - 1337

JO - Biochimica et Biophysica Acta - Molecular Cell Research

JF - Biochimica et Biophysica Acta - Molecular Cell Research

SN - 0167-4889

IS - 8

ER -